LAX.SH
MEDPLUS HEALTH SERV LTD·PHARMACEUTICALS 66.37·Retailing Companies
Price
594.7
-0.69%52W Range
Market Cap
₹7,144.55 Cr
Traded: ₹3.68 Cr (0.05%) 0.0x
Free Float: ₹1,172.42 Cr (0.31% of FF traded)
Volume · 60D trend
62 K 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | +8.0% | +8.0% | +8.0% | -- | -- | Stable |
| Sales | +15.0% | +18.0% | +15.0% | -- | +12.0% | Decelerating |
| Profit | +37.0% | +29.0% | +67.0% | -- | +50.0% | Stable |
| Return | -- | -- | +12.0% | +7.0% | -- | Decelerating |
Quarterly Results
Mar 2023
Dec 2022
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023PDF ↗ | Sep 2023PDF ↗ | Jun 2023PDF ↗ | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,880 | 1,864 | 1,806 | 1,679 | 1,543 | 1,510 | 1,561 | 1,576 | 1,489 | 1,490 | 1,441 | 1,409 | 1,284 | 1,253 | 1,190 |
| Expenses | 1,746 | 1,695 | 1,648 | 1,530 | 1,412 | 1,373 | 1,429 | 1,452 | 1,395 | 1,385 | 1,350 | 1,324 | 1,213 | 1,171 | 1,119 |
| Operating Profit | 133 | 169 | 159 | 149 | 131 | 136 | 133 | 124 | 94 | 106 | 92 | 85 | 71 | 82 | 72 |
| Other Income | 20 | 21 | 18 | 17 | 15 | 16 | 13 | 12 | 9 | 10 | 10 | 10 | 9 | 14 | 11 |
| Interest | 33 | 33 | 31 | 29 | 27 | 27 | 26 | 25 | 25 | 25 | 24 | 24 | 23 | 22 | 21 |
| Depreciation | 78 | 76 | 73 | 69 | 66 | 64 | 62 | 63 | 60 | 59 | 57 | 55 | 52 | 56 | 46 |
| Profit Before Tax | 42 | 80 | 73 | 69 | 53 | 61 | 57 | 48 | 18 | 32 | 20 | 16 | 5 | 17 | 16 |
| Tax % | 21.0% | 20.0% | 21.0% | 19.0% | 20.0% | 16.0% | 19.0% | 19.0% | 19.0% | -5.0% | 31.0% | 12.0% | 26.0% | -54.0% | 17.0% |
| Net Profit | 33 | 64 | 58 | 56 | 42 | 51 | 46 | 39 | 14 | 34 | 14 | 15 | 4 | 27 | 13 |
| Exceptional Items | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| EPS (Rs) | 2.8 | 5.3 | 4.8 | 4.6 | 3.5 | 4.3 | 3.8 | 3.2 | 1.2 | 2.8 | 1.1 | 1.2 | 0.3 | 2.2 | 1.1 |
| Sales Growth (YoY) | -- | 23.5% | 15.7% | 6.5% | 3.6% | 1.3% | 8.3% | 11.9% | 15.9% | 19.0% | 21.1% | 25.7% | 29.3% | 29.7% | -- |
| Sales Growth (QoQ) | -- | 3.2% | 7.6% | 8.8% | 2.2% | -3.3% | -0.9% | 5.8% | -0.1% | 3.4% | 2.3% | 9.7% | 2.5% | 5.3% | -- |
| OP Growth (YoY) | 1.5% | 24.3% | 19.5% | 20.2% | 39.4% | 28.3% | 44.6% | 45.9% | 32.4% | 29.3% | 27.8% | -- | -- | -- | -- |
| OP Growth (QoQ) | -21.3% | 6.3% | 6.7% | 13.7% | -3.7% | 2.3% | 7.3% | 31.9% | -11.3% | 15.2% | 8.2% | 19.7% | -13.4% | 13.9% | -- |
| Profit Growth (YoY) | -21.7% | 24.6% | 26.0% | 43.3% | 195.0% | 53.7% | 234.2% | 166.1% | 278.9% | 25.7% | 2.4% | 121.6% | 18.4% | 127.0% | -22.0% |
| EPS Growth (YoY) | -- | 24.2% | 25.9% | 42.9% | 195.0% | 53.8% | 233.0% | 165.6% | 275.0% | 25.1% | 2.7% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | 10.6% | 4.1% | 30.8% | -17.5% | 12.0% | 18.2% | 170.0% | -57.0% | 142.6% | -5.7% | 281.3% | -85.7% | 99.1% | -- |
| OP Margin | -- | 9.1% | 8.8% | 8.9% | 8.5% | 9.0% | 8.5% | 7.9% | 6.3% | 7.1% | 6.4% | 6.0% | 5.5% | 6.5% | 6.0% |
| Net Margin | -- | 3.4% | 3.2% | 3.3% | 2.7% | 3.4% | 3.0% | 2.5% | 0.9% | 2.3% | 1.0% | 1.1% | 0.3% | 2.1% | 1.1% |
| Material Cost % | -- | 74.0% | 74.0% | 74.0% | 74.0% | 73.0% | 75.0% | 76.0% | 78.0% | 77.0% | 78.0% | 78.0% | 79.0% | 77.0% | 78.0% |
| Employee Cost % | -- | 13.0% | 13.0% | 13.0% | 13.0% | 13.0% | 12.0% | 11.0% | 11.0% | 11.0% | 11.0% | 11.0% | 11.0% | 12.0% | 12.0% |
| P/S | 0.99 | 1.38 | 1.67 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 33.91 | 43.32 | 52.71 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 3.62 | 4.83 | 5.93 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Intimation of Earnings Calls for the quarter and half-year ended September 30, 2026
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 07, 2026 for Lone Furrow Investments Pvt Ltd
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on October 07, 2026 for Agilemed Investments Pvt Ltd
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October ....
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on October ....
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018
Credit Rating-Reaffirmed for Optival Health Solutions Private Limited, a Material Subsidiary of the Company.
Trading Window Closure under SEBI (Prohibition of Insider Trading) Regulations, 2015
Medplus Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve the Un-audited Standalone ....
Board comments on fine levied by the Exchange
Outcome of Board meeting under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations)
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on August ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 26, 2026 for Agilemed Investments Pvt Ltd
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
Submission of Voting results Along with Scrutinizer''s Report of the 20th Annual General Meeting of the company.
Summary Proceedings of 20th Annual General Meeting of the Company held on August 17, 2026
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 29, 2026 for Lone Furrow Investment Pvt Ltd
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on July ....
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on July 29, 2026 for Agilemed Investments Pvt Ltd
The Exchange has received the Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011 on July ....
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for ICICI Prudential Mutual Fund
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Newspaper Publication - for completion of dispatch of Notice of 20th Annual General Meeting.
Submission of Transcript of Earnings Call
Outcome of the Board meeting
20th Annual Report of the Company for the Financial Year 2025-26 along with Notice to the Shareholders for Annual General Meeting
BRSR for F.Y. 2025-26
Notice of 20th AGM of the Company for the F.Y.2025-26
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Submission of Newspaper Clippings
Submission of Audio Recordings of Earnings Call
Newspaper Publication - Information regarding the 20th Annual general Meeting of the Company to be held on August 17, 2026 through Video Conferencing/ Other Audio Visual Means
Request to Ignore Inadvertent Filing of Investor Presentation
Request to Ignore Inadvertent Filing of Investor Presentation
Request to Ignore Inadvertent Filing of Investor Presentation.
Request to ignore Inadvertent Filing of Investor Presentation.
Request to Ignore Inadvertent Filing of Investor Presentation
Outcome of Board meeting under SEBI (Listing Obligation and Disclosure requirements) Regulations 2015 (Listing Regulations)
Intimation of Investor Presentation
Intimation of Appointment of Company Secretary and Compliance Officer
Presentation for Earnings Call with Analysts/Instituitional Investors on Un-Audited Financials Results for the quater ended June 30, 2026
Outcome of Board meeting under SEBI (Listing Obligation and Disclosure requirements) Regulations 2015 (Listing Regulations)
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Discloure Requirements) Regulations, 2015
Schedule of Analysts or Institutional Investors Meet - Earnings Call with respect to audited Financial Results of the Company for the quarter ended June 30, 2026
Medplus Health Services Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/07/2026 ,inter alia, to consider and approve the un-audited Standalone ....
Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015
Concalls
20Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024May 2024
31 May 2024Feb 2024
29 Feb 2024Feb 2024
29 Feb 2024Nov 2023
30 Nov 2023Aug 2023
31 Aug 2023May 2023
31 May 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Feb 2023
28 Feb 2023Nov 2022
30 Nov 2022Aug 2022
31 Aug 2022Jun 2022
30 Jun 2022Feb 2022
28 Feb 2022Held by ETFs
3 ETFs hold medplus · sorted by weight
Held by Mutual Funds
29 schemes hold medplus · sorted by weight